Free Newsletter
Top Story
Big Pharma testing waters with mobile tech
Developers of mobile technologies have made some inroads with deep-pocketed drugmakers, which have sought the help of new apps and devices to streamline the development, marketing and sales of meds. Tech and biopharma entrepreneurs are betting that Big Pharma has an appetite for more mobile innovations. Article
Latest News
Also Noted
> The University of North Carolina at Charlotte's growing informatics program aims to answer demand for people with data expertise in the healthcare and bioscience fields. Article
> Exco InTouch has tapped Mark Brincat, who previously worked in informatics at Pfizer ($PFE), to head product development of mobile healthcare applications. Item
> Complete Genomics ($GNOM) has published in the Journal of Computational Biology its computational methods for reading whole human genomes accurately. Release
> Datatrack International ($DATA) has redesigned its randomization and clinical supplies management software called "uIRT." Announcement
Read more >>Popular Comment Threads
Editor's Corner
PerkinElmer CEO arranges marriage between informatics, lab service biz
PerkinElmer ($PKI) has broken into the informatics field in a big way over the past year or so, and some people have wondered how the company known for providing lab instruments and reagents was going to adapt to the software business. Well, it turns out that PerkinElmer envisions a future in which biopharma labs integrate informatics systems and instruments in a seamless fashion, and the Waltham, MA-based company plans to roll up its software capabilities into its lab services business to reflect that vision. And the plan could mean that PerkinElmer would compete with major IT services outfits such as Cognizant for business from major biopharma laboratories.
Slideshow
10 social media lessons for pharma
The Dec. 27 draft guidance, "Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices" offers sound counsel but not much in the area of direct guidance. Nevertheless, there are valuable lessons to be learned--if you are willing to read between the numerated lines. The draft guidance doesn't address many of social media's (referred to in the document as "emerging electronic media") regulatory red flags such as adverse events, the question of property owner vs. property user, and a more precise discussion of what "sponsored" means.
From The Network
Press Releases
- Advaxis CEO Tom Moore Interviewed by OneMedPlace Regarding Preliminary Data
- Initial Clinical Data Reveal Potential of Tasimelteon to Reset the Body Clock in Non-24-Hour Sleep-Wake Disorder
- 2011 Achievements and 2012 Prospects BioAlliance Pharma Confirms the Dynamics of Its Core Business
- Bristol-Myers Squibb Delivers Solid Fourth Quarter Capping a Year Highlighted by New Product Approvals, Continued Execution of S
- IntelliCell Filed Patent Application for its Proprietary Method of Manufacturing Stromal Vascular Fraction Cells
- BioReference to Launch Groundbreaking Solid Tumor Genotyping Test through its GenPath Oncology Laboratory
